A Phase 2 interventional study of Transdermal estradiol gel in COVID-19, sponsored by Hamad Medical Corporation. Status unknown at 1 site in Qatar. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-21.
Sponsored by Hamad Medical Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in COVID-19 by Hamad Medical Corporation — none open to participants now, none under way, none of them phase 3. COVID-19 · Hamad Medical Corporation.
Among the 17 studies in COVID-19 by Hamad Medical Corporation, this one has the largest planned enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2021, is one of 2 in phase 2, and was the 11th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →None of the 17 studies in COVID-19 by Hamad Medical Corporation is open now. The open studies under COVID-19, anywhere →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 4 · Phase 4 1
First in 2020; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 200 across the 11 interventional studies, 850 across the 6 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hamad Medical Corporation is the lead sponsor of 139 studies on the registry; 27 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in COVID-19 by Hamad Medical Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this trial is to determine whether oestrogen treatment mitigates disease progression and severity in confirmed COVID19.
It is known that (i) women are relatively protected from the impacts of other respiratory viruses, and that oestrogen may partly mediate this effect (ii) Oestrogen protects rodents from SARS-CoV-1 related mortality (iii) Women are relatively protected from developing or dying from severe COVID-19 and (iv) Postmenopausal women taking oestrogen replacement appear less likely to suffer Covid19-related critical illness. These effects may be mediated through oestrogen-related immunomodulation. In addition, however, 17β estradiol reduces expression of ACE2 (the receptor protein through which SARS-CoV-2 gains cellular entry) in tissues such as the kidney. As such, supplemental oestrogen may represent an effective therapy for Covid19.
We will randomise adult men and postmenopausal women with confirmed Covid19 disease to receive 10 days of transdermal oestrogen (3mg/day). The primary endpoint will be evidence of disease progression, indicated by hospitalisation (mild cases) or need for mechanical ventilation or death within 28 days of randomisation for those hospiatlsied. Secondary outcomes will include hospital mortality, duration of hospital admission, admission to ICU/ HDU facility, ICU/ HDU length of stay, need for renal replacement therapy, receipt and duration of invasive mechanical ventilation, cause-specific mortality and time to being fit for hospital discharge
.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Women:
Men:
Any subject:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive standard care + transdermal 17ß-estradiol gel (3 mg) for ten days.
Drug: Transdermal estradiol gel
Patients will receive only standard care.
Patients will receive standard care +/- (randomsed 1:1) transdermal 17ß-estradiol gel (3 mg; applied to forearm, upper arm and shoulder) for ten days.
Also known as: oestrogel, estrogel
Evidence of disease progression for mild cases
Proportion hospitalised within 28 days
Time frame: 28 days
Evidence of disease progression in hospitalised patients (moderate and severe cases)
Proportion requiring mechanical ventilation or dying within 28 days
Time frame: 28 days
Hospital mortality
Rate of mortality
Time frame: 28 days
Duration of hospital admission
Length of stay at hospital
Time frame: 28 days
Admission to ICU/ HDU facility
Length of stay at ICU/HDU facility
Time frame: 28 days
Need for renal replacement therapy
Proportion requiring renal replacement therapy
Time frame: 28 days
Ventilation
Proportion requiring mechanical ventilation within 28 days
Time frame: 28 days
Time to being fit for hospital discharge
Time of discharge
Time frame: 28 days
Start is estimated for May 2021; primary completion for Feb 2022, 9 months later.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's planned 9 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Estradiol